Lebrikizumab Pen Ease of Use in Participants With Atopic Dermatitis

Clinical trial NCT06444165 · COMPLETED

Trial details

NCT number: NCT06444165
Sponsor: Eli Lilly and Company
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Atopic Dermatitis

Start date: 2024-06-04
Primary completion: 2024-06-10
Enrollment: 55

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.